The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway is involved in the regulation of tumor-related immune processes, and it is a key target of cancer immunotherapy, which attempts to suppress immune escape and enhance antitumor immunity for the durable regression of malignant tumors of LC [132–134]. The gene discussed is CD274; the disease is neoplasm.